about
Changes in body weight and psychotropic drugs: a systematic synthesis of the literatureSymptom control and patient adherence to treatment: key goals in the treatment of psychosis.Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.Pharmacotherapy of first-episode psychosis.Relationship of atypical antipsychotics with development of diabetes mellitus.Clinical utilization of atypical antipsychotics in pregnancy and lactation.Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?Effect of Early Intervention with Omega-3 on Insulin Resistance in Patients Initiated on Olanzapine with either Sodium Valproate or Lithium: A randomized, Double-blind, Placebo-Controlled Trial.Association between antipsychotic drugs and diabetes.Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot studyWeight gain in antipsychotic-naive patients: a review and meta-analysis.Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex.Belgian consensus on metabolic problems associated with atypical antipsychotics.Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.The impact of weight gain associated with atypical antipsychotic use in schizophrenia.Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication: Literature Review.Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5'-monophosphate-activated protein kinase.Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.Calcium Channel Blockers as Drug Repurposing Candidates for Gestational Diabetes: Mining large scale genomic and electronic health records data to repurpose medications.
P2860
Q28728401-322D5B1E-20B2-45D7-A806-CBF383D6481AQ34450843-3D75C8F7-5035-4BA5-B4B4-6760605DCE9DQ34595255-11B11309-1812-4FF0-9A82-2B63A27C1E1FQ35100107-000B4695-EC84-4AEA-AF66-7CB763CEAD89Q35124708-019651FC-5265-4A7A-B8A3-8C3ECA922CF7Q35591014-3D598735-86B4-4713-86D9-47F700D93E2DQ35776755-BECE0623-26E6-4C1D-975D-B55E2A1B58DCQ36040749-B7B62523-7767-4A05-A68F-ADCBAB6F3326Q36197756-A21B9512-1AC2-411C-979A-3CBEF8E0829BQ36382695-FE04739B-6F40-4C82-A68B-81A6E2D46B19Q36929181-CC8C9116-91C3-4E02-9784-1B17A3D8A0B2Q37060012-365C68E3-DD22-4338-8EA4-5F4A85DA2BF2Q37572952-4575BFC4-DCE1-4A50-B3FF-5DCB6CEECF1CQ38078561-D0A1F2BD-A645-4A1F-A850-4A72519DB33BQ38220364-309C03DE-6DC9-4525-9EB2-8E108ADE002AQ38253580-D66297A9-73EC-4F6C-8B6A-CF48E9DFDC7EQ38777526-B359AF44-8844-44F2-A83C-4F0A19EBA0D1Q42358277-F0B0D252-0452-4E2D-9DFD-B6C3AF6D2027Q44986103-243C8FCA-0272-497F-BB62-9A89609168C7Q46358333-68C7B6D4-DE19-4A62-AED3-B47CA3FAD4ACQ47581724-A84C6B51-F7BD-49B1-80C0-6B2B45903DA1Q49968228-AF92BC4F-0FD2-437D-8BF8-93DA743EA221
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Glucose intolerance with atypical antipsychotics.
@en
Glucose intolerance with atypical antipsychotics.
@nl
type
label
Glucose intolerance with atypical antipsychotics.
@en
Glucose intolerance with atypical antipsychotics.
@nl
prefLabel
Glucose intolerance with atypical antipsychotics.
@en
Glucose intolerance with atypical antipsychotics.
@nl
P2093
P1433
P1476
Glucose intolerance with atypical antipsychotics.
@en
P2093
Karin Hedenmalm
Malin Ståhl
Orjan Mortimer
P304
P356
10.2165/00002018-200225150-00005
P577
2002-01-01T00:00:00Z
P5875
P6179
1030362975